MU Health Care will join a select group of hospitals nationwide by participating in a clinical trial to determine whether plasma from those previously infected with novel Coronavirus (COVID-19) can benefit those currently fighting the virus.
A news release says in partnership with the U.S. Food and Drug Administration (FDA) and the American Red Cross, the Mayo Clinic trial is designed to test the belief that so-called “convalescent plasma” from recovered donors can be infused into current patients to fight a virus. It’s a strategy that has prevented and treated other infectious diseases. MU Health Care and more than 100 other hospitals nationwide have enrolled in the trial to help determine if this process can work against COVID-19.
Adults who have recovered from COVID-19 are encouraged to participate in this unpaid and voluntary program. Their donations can benefit MU Health Care patients who are seriously ill with COVID-19.
Other eligibility requirements for donors include a previously documented positive COVID-19 test, 14 days of no symptoms and a subsequent negative COVID-19 test.
Those eligible and interested in donating plasma for the project can go to the Convalescent Plasma Program’s webpage at https://u7061146.ct.sendgrid.net/ls/click?upn=4tNED-2FM8iDZJQyQ53jATUXp-2F2gNcGBD-2BWyePgKs5iDbijHONxPWXdRUQQD7Rb-2FKlDynXYdBNPj13iXrU1mvAr0vql8wu3zQmydQFc4gy-2BWI-3DCBlV_y9vMKVNJbqbjAoc4TUXW93uBxzSzx8Ko6Oz8yzqV342Ea-2FznOf4-2BlvkyxY6xkv3FXffDhgUIOCRl3DgCM9WUn-2BEdG4M22ozq1PZeswXoh27dqhJrDD20bCqAzq5I3i5zlwsHoXMU-2Bk2-2BX-2Be2ZrGPdWP36T805Rt-2B-2FCkelwoM9WnA9TptJlVQWQXzRwhBrO6YDNddyJPNDlko7BVTQsXUYmbfw8gwN6y-2FRiaQYXUkVDae81sZxTzBV28-2Fp8TRn3R4srl8rJcMSy9Cxho1LhknQ46sYHODm7YHA4-2FCjdwL61zsfpq8YHadgj0mC8rqo5kUP1nkpWt-2BdL-2FQYka29ai4WA-3D-3D.